This “Palmoplantar Keratoderma - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Palmoplantar Keratoderma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Palmoplantar keratoderma (PPK) is a group of skin conditions characterized by thickening of the skin on the palms of the hands and soles of the feet.PPK can be either acquired during the lifetime (more commonly) or inherited. Acquired PPKs may arise due to changes in a person's health or environment.] Inherited PPKs are caused by genetic mutations that result in abnormalities of keratin, a skin protein. Even widespread thickened skin (keratosis) over the palms and soles, A red band at the edges of the keratosis is frequent, Other keratotic lesions may appear on the tops of the hands, feet, knees, and elbows, Excessive perspiration, Nails may be thickened are common symptoms associated with PPK. Treatment options for PPK involve the use of Topical keratolytics, such as salicylic acid, Benzoic acid compounds.
"Palmoplantar Keratoderma - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Palmoplantar Keratoderma pipeline landscape is provided which includes the disease overview and Palmoplantar Keratoderma treatment guidelines. The assessment part of the report embraces, in depth Palmoplantar Keratoderma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Palmoplantar Keratoderma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Palmoplantar Keratoderma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
SGT-210: Sol-Gel technologies Ltd.
SGT-210 is a topically administered, epidermal growth factor receptor (EGFR) inhibitor. t is believed that SGT-210 will work to inhibit this action and thus address the excessive skin growth and thickening which results in the significant impairment associated with PPK disorders. Sol-Gel Technologies, Ltd. initiated a Phase 1clinical study of SGT-210, its novel, topical, epidermal growth factor receptor inhibitor in patients with punctate palmoplantar keratoderma type -1.
There are approx. 3+ key companies which are developing the therapies for Palmoplantar Keratoderma. The companies which have their Palmoplantar Keratoderma drug candidates in the most advanced stage, i.e. phase I include, Sol-Gel technologies Ltd.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Palmoplantar Keratoderma therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Palmoplantar Keratoderma drugs.
Geography Covered
- Global coverage
Palmoplantar Keratoderma Understanding
Palmoplantar Keratoderma: Overview
Palmoplantar keratoderma (PPK) is a group of skin conditions characterized by thickening of the skin on the palms of the hands and soles of the feet.PPK can be either acquired during the lifetime (more commonly) or inherited. Acquired PPKs may arise due to changes in a person's health or environment.] Inherited PPKs are caused by genetic mutations that result in abnormalities of keratin, a skin protein. Even widespread thickened skin (keratosis) over the palms and soles, A red band at the edges of the keratosis is frequent, Other keratotic lesions may appear on the tops of the hands, feet, knees, and elbows, Excessive perspiration, Nails may be thickened are common symptoms associated with PPK. Treatment options for PPK involve the use of Topical keratolytics, such as salicylic acid, Benzoic acid compounds.
"Palmoplantar Keratoderma - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Palmoplantar Keratoderma pipeline landscape is provided which includes the disease overview and Palmoplantar Keratoderma treatment guidelines. The assessment part of the report embraces, in depth Palmoplantar Keratoderma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Palmoplantar Keratoderma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Palmoplantar Keratoderma R&D. The therapies under development are focused on novel approaches to treat/improve Palmoplantar Keratoderma.
Palmoplantar Keratoderma Emerging Drugs Chapters
This segment of the Palmoplantar Keratoderma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Palmoplantar Keratoderma Emerging Drugs
SGT-210: Sol-Gel technologies Ltd.
SGT-210 is a topically administered, epidermal growth factor receptor (EGFR) inhibitor. t is believed that SGT-210 will work to inhibit this action and thus address the excessive skin growth and thickening which results in the significant impairment associated with PPK disorders. Sol-Gel Technologies, Ltd. initiated a Phase 1clinical study of SGT-210, its novel, topical, epidermal growth factor receptor inhibitor in patients with punctate palmoplantar keratoderma type -1.
Palmoplantar Keratoderma: Therapeutic Assessment
This segment of the report provides insights about the different Palmoplantar Keratoderma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Palmoplantar Keratoderma
There are approx. 3+ key companies which are developing the therapies for Palmoplantar Keratoderma. The companies which have their Palmoplantar Keratoderma drug candidates in the most advanced stage, i.e. phase I include, Sol-Gel technologies Ltd.
Phases
The report covers around 3+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Palmoplantar Keratoderma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Palmoplantar Keratoderma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Palmoplantar Keratoderma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Palmoplantar Keratoderma drugs.
Palmoplantar Keratoderma Report Insights
- Palmoplantar Keratoderma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Palmoplantar Keratoderma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Palmoplantar Keratoderma drugs?
- How many Palmoplantar Keratoderma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Palmoplantar Keratoderma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Palmoplantar Keratoderma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Palmoplantar Keratoderma and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Sol-Gel Technologies Ltd.
- Krystal Biotech Inc.
Key Products
- SGT-201
- KB-105
Table of Contents
IntroductionExecutive Summary
Palmoplantar Keratoderma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Palmoplantar Keratoderma - Analytical Perspective
In-depth Commercial Assessment
- Palmoplantar Keratoderma companies' collaborations, Licensing, Acquisition - Deal Value Trends
Palmoplantar Keratoderma Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
SGT-201: Sol Gel Technologies Ltd.
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Palmoplantar Keratoderma Key Companies
Palmoplantar Keratoderma Key Products
Palmoplantar Keratoderma - Unmet Needs
Palmoplantar Keratoderma - Market Drivers and Barriers
Palmoplantar Keratoderma - Future Perspectives and Conclusion
Palmoplantar Keratoderma Analyst Views
Palmoplantar Keratoderma Key Companies
AppendixList of Tables
Table 1 Total Products for Palmoplantar Keratoderma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Palmoplantar Keratoderma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Sol-Gel Technologies Ltd.
- Krystal Biotech Inc.
